I added MyeloXen to the phase 2 list based on this news report.
Archive for updates
I moved Tecfidera from phase 3 to approved based on this FDA press release.
I added “Raltegravir (Isentress) (Queen Mary University of London)” to the phase 2 list. This is a really interesting one. It is an antiretroviral used to combat HIV. For MS, it is hypothesized to work against MS-associated endogenous retrovirus, and also possibly against Epstein-Barr virus. Unfortunately, there isn’t a big company behind it, so it might be hard to push this one past an initial, small phase 2 trial unless the results are spectacular. I’m hoping for spectacular…
I moved GNbAC1 from phase 1 to phase 2, based on GeNeuro’s website. This one is a monoclonal antibody (mAb) to prevent the inflammatory and autoimmune cascades induced by the multiple sclerosis-associated retrovirus (MSRV).
I added “Olesoxime (TRO19622) (Trophos)” to the phase 2 list based on this news article.
Woohoo! Aubagio was approved by the FDA on September 13, 2012. I moved it from phase 3 to the approved list. It’s a good day.
Aubagio used to be known as Teriflunomide, is an oral drug intended for the treatment of RRMS, had efficacy roughly equivalent to the CRABs and had no scary side-effects (unless you consider hair loss scary…and I might).
I have been waiting for this one for a long time. ShK-186 has entered phase 1, in the Netherlands.
ShK-186 inhibits the Kv1.3 potassium ion channel. Kineta’s program is the first Kv1.3-specific inhibitor advanced into the clinic. Kv1.3 has been a target of industry efforts for its role in instigating activation of effector memory T-cells, which are major mediators of autoimmune disease. Kineta scientific advisor and University of California, Irvine Professor, K. George Chandy and his collaborators invented ShK-186 by modifying natural sea anemone-derived peptide inhibitors of Kv1.3. ShK-186 can reduce disease symptoms and pathology in animal models of MS without broadly suppressing the immune system.